{'fraction_non_alphanumeric': 0.012345679012345678, 'fraction_numerical': 0.006734006734006734, 'mean_word_length': 5.656716417910448, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Analysis of State Medicaid Agency Performance in Relation to Incentivizing the Provision of H1N1 Immunizations to Eligible Populations

Immunization is one of the most effective and cost effective prevention measures available. The benefits of immunization are even more pronounced for the Medicaid population, where beneficiaries have greater health care needs and higher health risks than other individuals in the U.S. All Medicaid enrolled children under the age of 21 are legally entitled to all immunizations recommended by the Advisory Committee on Immunization Practices (ACIP). Recent guidelines issued by the Centers for Medicare and Medicaid Services (CMS) clarify that costs associated with the administration of the H1N1 vaccine by providers whose treatments fall into required coverage categories is itself a required benefit. Specifically the CMS guidance specifies as follows: